February 17, 2021
“Cortexyme, Inc. (CRTX)… Overall, Cortexyme has a Moderate Buy rating from the analyst consensus, with 6 recent reviews breaking down 4 to 1 to 1, Buy-Hold-Sell. The stock’s $83.60 average price target suggests that Wall Street sees a high potential here,… Continue Reading…
Recent Comments